Selective Attenuation by N-0861 (N6-Endonorboran-2-yl-9-Methyladenine) of Cardiac A1Adenosine Receptor–Mediated Effects in Humans

Authors:
Publisher website
Google Scholar
Abstract
BackgroundTo determine the adenosine receptor subtype selectivity of the novel antagonist N-0861, the A1and A2receptor–mediated cardiac effects of adenosine were investigated in 13 patients during continuous intravenous infusion and boluses of adenosine before and after intravenous infusion of N-0861.Methods and ResultsMeasurements of the atria-to-His (A-H) interval, chest pain severity, and coronary blood flow velocity were made before and after low-dose (69 μg · kg−1· min−1) intravenous infusion and bolus (2.5 mg) adenosine. Two doses of N-0861 were infused intravenously, and the adenosine protocol was repeated. N-0861 0.25 mg/kg abolished the negative dromotropic effect (A-H interval prolongation) and chest discomfort experienced during infusion of adenosine and attenuated discomfort observed during the boluses of adenosine; however, the increase in coronary blood flow velocity was not significantly affected.ConclusionsThese actions of N-0861 support the concept that the negative dromotropic effect and anginalike pain caused by adenosine are A1adenosine receptor–mediated, whereas the increase in coronary blood flow velocity is due to activation of A2adenosine receptors. N-0861 appears to be an effective and selective A1adenosine receptor antagonist in humans.

This publication has 21 references indexed in Scilit: